| Authors: |
van Hattem CC; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.; Medicines Evaluation Board, Utrecht, the Netherlands., de Jong AJ; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., de Groot JS; Medicines Evaluation Board, Utrecht, the Netherlands., Hoekman J; Innovation Studies, Copernicus Institute of Sustainable Development, Utrecht University, Utrecht, the Netherlands., Broekman KE; Medicines Evaluation Board, Utrecht, the Netherlands.; Department of Medical Oncology, University Medical Centre Groningen, Groningen, the Netherlands., Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, University of Amsterdam, Amsterdam, the Netherlands., van Hennik PB; Medicines Evaluation Board, Utrecht, the Netherlands., Bloem LT; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands L.T.Bloem@uu.nl. |
